What Rock Labs does

Rock Labs is a UK-based, privately held health technology company developing point-of-care cortisol monitoring technology for endocrine health management, with particular focus on adrenal insufficiency. The company serves two primary customer personas: patients and carers managing hormonal conditions who lack practical day-to-day monitoring tools, and clinicians supporting those patients who need longitudinal visibility beyond clinic visits. Its business is presently structured as pre-revenue clinical development rather than commercial sales, with the company explicitly stating its technology is in clinical trials and not available outside regulated pathways.

The company's product portfolio centers on two offerings. The core Cortisol Monitoring Technology is a point-of-care sensing programme combining proprietary sensing hardware, algorithms, secure data handling, and analysis software designed to support both patients and clinicians within regulatory pathways. A complementary Symptom-Tracker mobile application has been developed to help parents manage childhood adrenal insufficiency at home via patient-reported data. Technical differentiation is grounded in domain specialisation in endocrine health rather than general-purpose biosensing, with hardware, algorithms, and user experience refined in collaboration with NHS clinical teams and patients.

Rock Labs operates on a planned subscription/recurring revenue model to be activated post-approval, with anticipated distribution routed through health systems, payers, and pharmaceutical partners rather than direct consumer sales. Its commercial pipeline is anchored by three core strategic partners: the NHS, Royal Manchester Children's Hospital (clinical co-development), and The Pituitary Foundation (patient advocacy and lived-experience input). Company research has been disseminated through poster abstracts at the British Society for Paediatric Endocrinology and Diabetes (BSPED) annual meetings in 2024 and 2025, published in Endocrine Abstracts. The company is small (1-10 employees), bootstrapped or grant-funded to date, and led by Founder & CEO Ben Marinic with an advisory bench including Prof. Indi Banerjee (paediatric endocrinology) and Bev Hurley CBE (commercialisation).

Name

Rock Labs

Legal name

Rock Labs Ltd

Website

https://rocklabs.co

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Rock Labs is a UK-based pre-revenue health technology company developing point-of-care cortisol monitoring sensing hardware and a symptom-tracking mobile app for patients with hormonal conditions, currently in early clinical trials with the NHS.

Ownership category

akta.pro rank

Product category

Digital Health — Endocrine Health Monitoring

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

Keywords

• Cortisol monitoring
• Endocrine health platform
• Digital health sensing
• Clinical decision support
• Symptom tracking app

Headquarters

HQ city

City Of London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pre-Revenue / Development Stage: Rock Labs is in clinical trials stage with its technology. The company works with health systems, payers, and pharmaceutical partners who help make tools available to patients when evidence and approvals support that. No commercial revenue has been generated as the technology is not yet a finished product.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Rock Labs develops an integrated point-of-care cortisol monitoring platform that combines proprietary sensing hardware, secure data handling, and software with AI/ML analytics to support patients and clinicians in managing cortisol-related hormonal conditions such as adrenal insufficiency. A complementary symptom-tracker mobile application supports home management, particularly for paediatric adrenal insufficiency. The technology is currently in early clinical trials in collaboration with the NHS and is not yet a commercially available finished product.

Product overview

Rock Labs is developing an integrated endocrine health platform focused on cortisol monitoring. The core offering consists of a point-of-care cortisol monitoring technology (currently in early clinical trials) that combines sensing hardware, secure data handling, and analysis software to support both patients and clinicians. A complementary symptom-tracker mobile application has been developed for home management of childhood adrenal insufficiency. The platform is designed to provide precise, longitudinal insight into cortisol-related health, with an emphasis on real-life usability rather than clinical settings alone.

Differentiator

Problem solved

Functional benefit

Products and services

• Cortisol Monitoring Technology An integrated point-of-care cortisol monitoring platform combining proprietary sensing hardware, secure data handling, and analysis software (including AI/ML) to provide longitudinal insight into cortisol-related health. Designed to support both patients living with hormonal conditions such as adrenal insufficiency and the clinicians who care for them. Currently in early clinical trials and not yet a finished commercial product.
• Symptom-Tracker App A mobile application designed to help parents manage childhood adrenal insufficiency at home by enabling symptom tracking and supporting optimisation of treatment plans through patient-reported data. Developed in collaboration with NHS clinical teams and The Pituitary Foundation with lived-experience input from families.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• NHScoreStrategic or Co-development PartnerNHS partnership for developing and validating endocrine health monitoring technologies. The collaboration supports making Rock Labs tools available to patients through health system pathways when evidence and approvals support that.
• Royal Manchester Children's HospitalcoreStrategic or Co-development PartnerClinical collaboration with NHS clinical teams at Royal Manchester Children's Hospital for developing monitoring tools, particularly for adrenal insufficiency in pediatric patients. Team members have co-authored research with hospital staff.
• The Pituitary FoundationcoreStrategic or Co-development PartnerPatient advocacy partnership with The Pituitary Foundation including lived-experience input into product development. Collaboration ensures tools are grounded in real patient and carer needs.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Dexcom: Leading continuous glucose monitoring company with established hardware, software, and clinical evidence infrastructure. Comparable business model (continuous biochemical sensing + app + clinical decision support) and a benchmark for what successful endocrine monitoring scale looks like.
• Roche Diagnostics: Global diagnostics incumbent with established cortisol immunoassays and immunoassay platforms used in clinical labs. Comparable on the diagnostic substance/testing side; an incumbent Rock Labs must differentiate against on performance, accessibility, and patient experience.
• Abbott (Diagnostics & Diabetes Care): Global diagnostics and medical device incumbent operating FreeStyle Libre CGM and a broad immunoassay portfolio that includes cortisol testing. Comparable on the cortisol diagnostic side and a likely competitive threat via scale, distribution, and clinical evidence resources.

Emerging players

• Function Health: Comprehensive at-home biomarker and lab testing platform with a software layer for longitudinal tracking and clinical decision support. Comparable in combining diagnostic testing, consumer health focus, and longitudinal data platform, though broader than endocrine.
• Huma: UK-headquartered digital health platform combining remote patient monitoring, decentralized clinical trials, and AI-driven decision support. Comparable in combining RPM software, clinical partnerships, and pharma/health-system GTM, but operating at much broader scale.
• Biofourmis: AI-driven remote patient monitoring and decentralized clinical trial platform focused on chronic conditions. Comparable technology stack (sensors + software + AI for clinical decision support) and enterprise health-system go-to-market motion.
• Spren: Digital health startup using sensors and software to track hormonal biomarkers (cortisol) via wearable signals. Closely comparable in combining novel sensing with a software/AI layer to surface cortisol insight for consumers and clinicians.

Direct peers

• Thriva: UK-based at-home blood testing service delivering biomarker results to consumers with clinician follow-up. Comparable to Rock Labs as a UK digital health company translating lab diagnostics into consumer/patient-friendly monitoring, though Thriva is further along commercially and not focused on cortisol.
• Medichecks: UK-based at-home blood testing platform offering a wide range of hormone and endocrine panels, including cortisol. Similar at-home diagnostic model and UK regulatory pathway, with overlap in target endocrinology use cases.
• Levels Health: US consumer metabolic monitoring company using continuous glucose sensing plus software to give users real-time insight and clinical decision support. Closely comparable model: sensing hardware + software + AI for day-to-day metabolic/hormonal condition management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/rock-labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rock Labs